Data as of Jul 29
| +0.06 / +0.12%|
Hospira, Inc. is a pharmaceutical and medication drug delivery company, which engages in providing injectable drugs and infusion technologies. Its portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. The company operates its business through three reportable segments: Americas; Europe, Middle East and Africa (EMEA); and Asia Pacific. The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the Asia Pacific segment includes Asia, Japan, Australia and New Zealand. In all segments, Hospira sells a broad line of products, including Specialty Injectable Pharmaceuticals which includes generic injectables and proprietary specialty injectables; Medication Management which includes infusion pumps, related software and services, dedicated administration sets, gravity administration sets, and other device products; Other Pharmaceuticals which include large volume intravenous solutions, nutritionals and contract manufacturing services. Its products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. Hospira was founded on September 16, 2003 and is headquartered in Lake Forest, IL.
|F. Michael Ball||Chief Executive Officer & Director|
|Matthew R. Stober||Senior Vice President-Operations|
|Thomas E. Werner||Chief Financial Officer & Senior Vice President|
|Daphne E. Jones||Chief Information Officer & Senior Vice President|
|Sumant Ramachandra||Chief Scientific Officer & Senior Vice President|